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A B S T R A C T   
The involvement of cancer stem cells (CSCs) in driving tumor dormancy and drug resistance is well established. 
Most therapeutic regimens however are ineffective in targeting these regenerative populations. We report the 
development and evaluation of a monoclonal antibody, mAb150, which targets the metastasis associated anti-
gen, Annexin A2 (AnxA2) through recognition of a N-terminal epitope. Treatment with mAb150 potentiated re- 
entry of CSCs into the cell cycle that perturbed tumor dormancy and facilitated targeting of CSCs as was validated 
by in vitro and in vivo assays. Epigenetic potentiation further improved mAb150 efficacy in achieving total 
tumor regression by targeting regenerative populations to achieve tumor regression, specifically in high-grade 
serous ovarian adenocarcinoma.   
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Introduction 
Disease relapse in cancer is often mediated by a small quiescent 
population of cancer stem cells (CSCs), which escape chemotherapy and 
adoptively propagate new tumors [1]. The notorious characteristics of 
CSCs viz. self-renewal, multi-lineage differentiation, tumor initiation, 
invasion/migration, and drug resistance are presently realised as road-
blocks in contemporary therapeutics [2–4]. Most promising drugs at the 
pre-clinical levels often eliminate rapidly proliferating cells within tu-
mors. This is an incomplete evaluation of drug cytotoxicity since it fails 
to account for slow-cycling or quiescent populations that contribute to 
disease relapse and compromise the efficacy of therapeutic regimens 
[2–4]. This necessitates the development of specific drugs that could 
target CSCs and other dormant/ slow-cycling populations within tu-
mors. Monoclonal antibody (mAb)-based immunotherapy promises 
specific targeting of tumor cells with minimal side effects and an added 
benefit of resurrecting host immune responses [5,6]. Several mAbs 
approved by Food and Drug Administration (FDA), USA, are reportedly 
successful in diverse cancers in the clinic including rituximab, trastu-
zumab, cetuximab, bevacizumab, and nivolumab; additional mAbs are 
either under FDA review or in phase 3 trials [7]. The clinical success of 
immune checkpoints inhibitors (ICI) viz. ipilimumab, tremelimumab, 
nivolumab, pidilizumab, atezolizumab and durvalumab further em-
phasizes the utility of mAbs against immune checkpoints such as 
CTLA-4, PD-1, and PDL-1 in solid tumors [6]. These successes, however, 
do not address the elimination of CSCs and other dormant/slow-cycling 
tumor cell populations which could reduce the risk of relapse. 
In the present report, we developed and characterized a monoclonal 
antibody viz. mAb150 that recognizes a 37 kDa antigen, consequently 
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identified as Annexin A2 (AnxA2/Annexin II). AnxA2 is a member of 
Annexin family of calcium-dependent phospholipid-binding proteins 
and is associated with several metastatic cancers [8]. The epitope 
recognized by mAb150 was identified at the N-terminal of AnxA2, which 
is essential for membrane localization and interactions with binding 
partners such as S100A10 [9]. Profiling AnxA2 expression across het-
erogeneous tumor cell populations revealed a high specificity of 
mAb150 for AnxA2-expressing CSC and progenitor populations in xe-
nografts, hence treatment with mAb150 could significantly reduce 
tumor burden by targeting these populations. Analysis of AnxA2 
expression networks and protein interactions further elucidated its 
contributions to cell migration and tumor metastasis. Treatment with 
mAb150 was also found to delay ascites formation and prolong survival 
in ovarian cancer xenograft models, which affirms its efficacy. 
Methods 
Drugs, cells, PKH labeling, tumor xenograft and treatment regimens 
All drugs and basic cell culture/biochemistry/proteomics reagents 
were procured from Sigma-Aldrich (St. Louis, MO, USA) unless other-
wise specified. A4, OVCAR3 and other cell lines were procured and 
cultured as described earlier [10]. PKH67 labeling of cells and genera-
tion of xenografts (labeled / unlabeled) has been described earlier [11, 
12]; subcutaneous injections of 5 × 106 for OVCAR3 or 2.5 × 106 cells 
for rest of the cell lines in 6–8-week-old female NOD/SCID mice were 
administered. MCF7 xenografts were developed with prior estradiol 
treatment as per established protocol [13]. Mice were bred and main-
tained at the NCCS Experimental Animal Facility; all procedures were 
carried out in accordance with the Institutional Ethical Animal Com-
mittee’s clearances, laws, and policies. mAb150 treatment was admin-
istered once tumors were palpable, as 3 injections per week (3D,150 μg 
protein/site) for 2 weeks followed by a week of recovery or 3 injections 
per week X 2 (6D). 5Aza-dC and HMTase inhibitor were administered 15 
days after initiation of A4 subcutaneous xenografts at tumor site in 
NOD/SCID mice at a final drug concentration of 5 mg/kg of body 
weight. On harvesting, tumor volumes were calculated as: Tumor Vol-
ume = Length x (Width2)/2 cm3 [14]. The PDX model was developed 
from tumor ascites obtained from a 65-year-old high grade serous 
ovarian cancer patient who presented with recurrent disease following 
two years of Paclitaxel-Carboplatin-NACT and liposomal doxycycline 
treatment. Ascites derived cells were washed 2–3 times with plain MEM, 
collected by centrifugation at 2000 rpm for 5 min; 5 × 106 cells were 
injected intraperitoneally in NOD/SCID mice for establishment of the 
PDXs. Tumor ascites formation was observed after 3 months, this was 
tapped, washed with PBS and injected into a new batch of mice. mAb150 
treatments were administered to the 5th passage of PDX. In the initial 
experiments with A4 xenografts (Figs.1B-iv, -v), effects of mAb150 were 
evaluated in comparison with those of IgM isotype control (Sigma-Al-
drich # M-5909). Limiting dilution assay was performed to evaluate 
tumor initiating potential. Briefly, tumor cells (5000, 10,000, or 20,000) 
were injected subcutaneously (1:1-matrigel: PBS) in NOD/SCID mice. 
Tumor formation was monitored for one month after injection. 
Antigen localization and immunoblotting 
Immunoblotting including preparation of whole cell protein lysates 
and subcellular fractions, protein denaturation, SDS-PAGE run, transfer 
and antibody probing followed by detection was performed as described 
earlier [15]. β-actin was used as internal control unless specified 
otherwise. Details of all antibodies used can be provided on request. 
Immunoprecipitation 
Whole cell proteins (A4) were prepared in RIPA (1 M Tris pH 7.4, 4 M 
NaCl, 0.5 M EDTA, NP-40, 10% SDS) buffer containing 1X protease 
inhibitor cocktail as described earlier [15]. Recombinant Anx1–12 
proteins were used at 500 μg concentration. mAb150 antibody (5 µg/mg 
protein) was incubated overnight with whole cell proteins (input) with 
respective internal controls at 4 ◦C. Further, anti-IgM agarose (Sigma 
Aldrich, #324,374) beads were used for retrieval of antibody-linked 
proteins, as previously described [15]. For all experiments and wher-
ever relevant, IgM isotype control (Sigma-Aldrich # M-5909) and bead 
controls were used. 
Antigen identification by MS/MS sequencing 
mAb150-immunoprecipitated proteins were resolved in 12.5% SDS- 
PAGE gel stained with mass-spectroscopy compatible Coomassie stain 
(Pierce, CA, USA). Individual protein bands (based on molecular weight) 
were excised, digested, desalted and purified for acquisition of spectra a 
4800 MALDI-TOF/ TOF mass spectrometer (AB Sciex, Framingham, MA) 
and protein identification performed using MASCOT (version 2.1; 
http://www.martixscience.com) on search engine against the SwissProt 
database as described earlier [16]. 
Construction and expression of Anxa2 deletion mutants 
AnxA2 protein was amplified using a cDNA clone (Origene 
RC205081) and cloned into the pGEX4T3 vector with a N-terminal GST 
tag. A series of 12 Anxa2 fragments (detailed in Fig. S4) were expressed 
in a similar manner. Protein expression was induced using 1 mM IPTG at 
22 ◦C for 16 h. Expressed proteins were extracted and sonicated in lysis 
buffer containing 1 M Tris (pH 8.0), 300 mM NaCl, 0.1% TritonX-100, 2 
mM PMSF and protease inhibitor cocktail (Roche). Lysate was clarified 
by centrifugation at 13,200 rpm at 4 ◦C for 30 min and the supernatant 
purified with GST-Sepharose beads (GE biosciences). Sequences of 
primers used for generation of these mutants are listed in Supplementary 
Data 2. 
MTT assay for cytotoxicity/cell viability analysis 
Cell viability on exposure to mAb150 (2–20 mg protein/ml), 5Aza- 
dC and CBB1007 (5 and 7 mmol respectively - standardised earlier) 
was assessed over 96 h using MTT assay. Following treatment, MTT 
(Sigma, 5 mg/ml) was added, and plate was incubated for 4 h at 37 ◦C in 
the dark. The insoluble formazan crystals were solubilized in acidified 
isopropanol and absorbance measured at 570 nm. Viability was calcu-
lated as a% ratio of test wells over the IgM isotype control (Sigma- 
Aldrich # M-5909). We further evaluated the neutralizing effects of 
mAb150, which revealed low IC50 values in high AnxA2-expressing cells 
and affirmed the high specificity of mAb150. Due to this specificity, a 
more accurate estimation of IC50 values would be the concentration 
required to reduce 50% of Anxa2 expressing cells in a population, which 
we termed as Anxa2 expression normalized IC50 (nIC50) values. 
Viability during in vitro migration assays was evaluated by treating cells 
with propidium iodide (200ug/ml) at specific time points after wound 
induction. Percent dead cells were quantified for thresholded phase- 
contrast and fluorescence images with the ‘Analyze Particles’ Plugin in 
the Fiji software. 
FACS staining and resolution of various tumor cell fractions for 
clonogenicity and in vitro tumorigenicity 
Resolution of the tumor regenerative hierarchy was based on a PKH 
label chase as described earlier [12, 17]. Briefly, freshly labeled PKH67 
cells and unlabeled tumor cells were used before each acquisition of 
xenograft fractionation as positive and negative controls, along with 
propidium Iodide (PI) and Hoechst–Pyronin Y-stained cells. Each 
PKH-derived fraction was analyzed independently with PI and 
Hoechst–Pyronin Y-based DNA content and cell cycle analysis. Together, 
this identified 18 discrete tumor cell fractions which were analyzed and 
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assayed for Clonogenicity and in vitro tumorigenicity as described 
earlier [12]. Flow cytometry was performed on BD FACS Aria II Sorp (BD 
Biosciences, San Jose, CA, USA), and data analyzed using the BD FACS 
Diva 6.0. mAb150 treated xenografts along with age-matched controls 
were harvested as per experimental schedule and processed for FACS 
based quantification of 18 tumor fractions. For comparisons between 
cell lines, FACS sorted treated versus control cells were similarly 
considered. Log2 (fold-change of the percent frequencies of residual 
tumor fractions) following mAb150 treatment were normalized with 
those of corresponding control tumor fractions using Pearson’s corre-
lation distance matrix, average linkage methods and one-way hierar-
chical clustering based heatmap generated using MeV 4.8.1 (TM4 
developer team, Boston, MA, USA). Functional clonogenicity assays 
were also performed and fold-change between control and 
mAb150-treated sets estimated. 
Spheroid formation and immunostaining 
5 × 104 sorted cells/well from each sorted tumor fraction were 
seeded in ultra-low attachment plate (Corning, Tewksbury, MA, USA) in 
MEM Medium containing 1% serum and incubated at 37 ◦C for 14 days 
before quantifying spheroids; images were captured on Olympus IX71 
microscope (Dulles, VA, USA). For immunostaining, spheroids were 
fixed with 4% paraformaldehyde and stained with mAb150 (1:10,000 
dilution) as described earlier [18]. 
Wound closure, cell invasion assays and migration mode (EMT, aCCM or 
pCCM) analysis 
Wound closure and cell invasion assays along with the analysis for 
migratory mode determination were performed as previously reported 
[18]. 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed using standard protocols. Briefly, 96-well 
plates were coated with the antigen (10μg/well) and incubated over-
night at 4 ◦C. Each well was washed with ~200 µL wash buffer and 
incubated with 200 µL blocking buffer per well for 1 h at room tem-
perature. 100 µL of standards and samples (in triplicate) were loaded in 
designated wells, incubated for 1 h at room temperature, washed 5 times 
with ~200 µL wash buffer. 100 µL of the antibody solution in blocking 
buffer (1:100) was added in each well, and incubated for 3 h at room 
temperature, washed 5 times with wash buffer and probed by adding 
streptavidin-HRP solution followed by TMB substrate solution. After 
adding stop solution, absorbance of each well at 450 nm was recorded 
with a plate reader. Data was normalized with that of IgM isotype 
control (Sigma-Aldrich # M-5909). 
Semi-quantitative reverse transcription-PCR 
Total RNA was isolated from cells using the Qiagen RNeasy minikit 
(Qiagen, Inc.) according to the manufacturer’s protocol and semi- 
quantitative reverse transcription-PCR was performed under standard 
conditions as described previously [19]. Amplified products were 
resolved on a 1.5% agarose gel; GAPDH was used as internal control. 
Details of primer sequences are listed in Supplementary Data 3. 
Immunohistochemistry (IHC) 
IHC was performed on xenografts as described earlier [20]. Briefly, 5 
µm sections were fixed at 60 ◦C for 1 h, deparaffinized in xylene, hy-
drated in ethanol-distilled water gradient and incubated for 30 min at 
pH 6 for heat-induced epitope retrieval (HIER). Peroxidase inactivation 
was performed by incubating sections in 3% H2O2 for 30 min (Quali-
gens, MA, USA), followed by 1x Blocking Solution for 10 min (Biogenex, 
CA, USA) and overnight incubation in primary antibody. Sections were 
washed, incubated with anti-rabbit HRP-conjugate (Jackson Labora-
tories, Inc., PA, USA) for 1 h, and color developed with DAB (Thermo 
Pierce, MA, USA); hematoxylin was used as a counterstain. Dehydrated 
sections were mounted in DPX (Qualigens, MA, USA). For all experi-
ments either IgM isotype (Sigma-Aldrich # M-5909) or controls without 
primary antibody were used. 
Prediction of binding epitope for Anxa2 
The sequence of AnxA2 was retrieved from UniProtKB - P07355, and 
its complete structure was prepared using two entries from Protein Data 
Bank – 1W7B and 4FTG. Five different prediction platform/servers were 
used for the prediction of AnxA2 epitopes – ABCpred, BepiPred-2.0, 
FBCPred, BCPred and Ellipro [21–24]. The part of protein sequence 
that was predicted as an output by all the five servers was considered as 
potential epitope region, sequences predicted by 4 out of 5 servers were 
processed. 
Statistical analysis 
Unless mentioned otherwise, all experiments were carried out at 
least in triplicate. Results are expressed as mean ± S.E.M. of 3 inde-
pendent experiments. Significant difference of mean values determined 
using two-tailed Student’s t-test (SigmaStat software; *P<0.05; 
**P<0.01; ***P<0.001). 
Results 
mAb150 development and identification of an immunogenic target protein 
A secretory hybridoma clone was developed by fusion of SP2/ 
0 myeloma cells with Balb/c mouse spleen-derived B cells previously 
primed with cell membrane proteins of an ovarian cancer stem-like cell 
line (A4; {Bapat, 2005 #35}; S.Data1;Fig.S1). The antibody secreted by 
this clone was isotyped as IgM kappa and designated mAb150. Immu-
noblotting of A4 cell lysates identified a 29–37 kDa protein as the an-
tigen recognized by mAb150 (Fig. 1A-i). Tryptic digestion of mAb150- 
immunoprecipitated protein, consequently sequenced by MALDI-TOF 
applying probablity-based mowse score with rational peptide 
sequence coverage and lower RMS identified human AnxA2 as the target 
protein (S.Data2;Fig.S2). Further validation was performed by probing 
either mAb150 immunoprecipitated (i) A4 cell lysates or (ii) purified 
commercial AnxA2 protein (Origene TP305081) with mab150 and 
commercial Annexin A2 antibody (sc-28,385) (Figs.1A-ii-v). The target 
protein was localized in membrane, cytoplasmic and nuclear fractions of 
A4 cell lysates (Figs.1A-vi, viii). Importantly, expression of AnxA2 in A4 
cells (Figs.1B-i-ii) correlated with growth inhibition by mAb150 as 
revealed in MTT assays (IC50–10μg). A significant reduction of A4 
xenograft volumes in mice treated with mAb150 (Figs.1B-iii-iv) was 
associated with a depletion of Anxa2 expressing cells thus, highlighting 
the target specificity of this neutralizing antibody (Fig.1B-v). 
mAb150 neutralizing effect correlates with Anxa2 expression in tumors 
Profiling surface expression of AnxA2 across a panel of 24 cancer cell 
lines (representing 9 different tumor types including ovarian, breast, 
prostate, colon, glioblastoma, lung, kidney, skin, and cervical cancer) 
revealed a cell system specific range of expression (14%–61.5%; 
Tables S1-S2). We further evaluated the neutralizing effects of mAb150, 
which revealed its low IC50 values in high AnxA2-expressing cells and 
affirmed the high specificity of mAb150. Due to this specificity, a more 
accurate estimation of IC50 values would be the concentration required 
to reduce 50% of Anxa2 expressing cells in a population, which we 
termed as Anxa2 expression normalized IC50. This is important since it 
would also provide a more accurate comparison of mAb150 efficacy 
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across a panel of cancer cell lines representing different tumor types 
with intrinsically different expression of Anxa2. Thus, normalized IC50 
values (nIC50) ranged between 12.04–172.9 μg/ml across the panel of 
cell lines tested (Fig. 2A), indicating differential efficacies of mAb150, 
being highest in glioma (U373) xenografts and lower in lung adeno-
carcinoma (A549) (Fig.S3A). 
Tumor regression was associated with reduced AnxA2 expression 
(maximal reduction in ovarian, A4 and least in cervical, ME180 xeno-
grafts). Derivation of nIC50 values in xenografts demarcated two 
response groups, ‘Group a’ (low AnxA2 expression, low mAb150 efficacy 
- OVCAR3, ME180, A549) and ‘Group b’ (high AnxA2 expression, high 
mAb150 efficacy and regression - A4, MCF7, A431, PC3, HT29, U373; 
Fig.2B; Table S3; Fig.S3). These data affirmed direct correlation between 
AnxA2 expression and mAb150 efficacy. Such specificity further led us 
to explore the modulation of AnxA2 expression by epigenetic drugs to 
reverse promoter methylation as reported earlier [12]. Treatment of A4 
and OVCAR3 cell lines with a combination of mAb150 with either a 
demethylating agent (5-Aza-Dc; 5 mM) or HMATase inhibitor (7 mmol) 
significantly increased AnxA2 expression and reduced cell growth 
(Figs.2C-D). This data suggests epigenetic potentiation could comple-
ment targeting of tumor cells by mAb150. 
Determination of mAb150 binding epitope across the Anxa2 protein 
sequence 
To identify the specific human Anxa2 epitope targeted by mAb150 
we performed sequential linear epitope prediction with publicly avail-
able algorithms (UniProtKB P07355; [22]). A higher epitope propensity 
spanning residues 4–41 at the N-terminal region of AnxA2 was thus 
predicted (Table S4). This linear prediction was validated by screening 
differential binding of mAb150 to peptide fragments representing 
distinct stretches of amino acids across the entire AnxA2 sequence (Ax1 
to Ax12; Figs.S4). This indicated maximal affinity of mAb150 towards 
Ax1 (Full length), Ax2 (Residues 1–169), Ax4 (Residues 1–113) and Ax7 
(Residues 1–50) fragments, all of which contain the N-terminal region of 
AnxA2 (Figs.3A-B,3E; anti-GST tag used as control). Immunoprecipita-
tion of Ax4, Ax5, Ax6, peptide fragments with mAb150 revealed pref-
erential binding for Ax4 and further with Ax7 (Figs.3C-E), which was 
confirmed through ELISA (Fig. 3F). 
Final validation of the predicted mAb150 linear epitope was ach-
ieved through ELISA by using synthetic, non-overlapping 10-mer pep-
tides covering amino acids 1–113 of the AnxA2 sequence (AP1-AP11). 
This revealed highest affinity of mAb150 for residues 11–20 (AP2) 
(Fig.3G-i; commercial AnxA2 antibody sc-166,762 recognizing C-ter-
minal epitope (region covering 324–339 residues) was used as negative 
control (Fig.3G-ii). Overall, these experiments confirmed that mAb150 
preferentially recognizes an epitope involving the N-terminal amino 
acids 11–20. 
We further mapped AnxA2 epitopes at atomic resolution by applying 
a 3D structure-based epitope prediction platform (Ellipro) and artificial 
intelligence (AI)-based prediction platform/servers (ABCpred, 
BepiPred-2.0, FBCPred, BCPred) that compute from knowledge-based B- 
cell epitopes/non-epitopic datasets. Mapping of AnxA2 N-terminal 1–50 
aa input sequence predicted a common epitope across all 5 platforms, 
the core of which comprised residues 16–21 further corroborating with 
the immunoreactivity observed between mAb150 and AP2 peptide 
(11–20 aa;Figs.3G-i;Figs.3Hi-ii). Molecular representation positioned 
this epitope on the surface of Anxa2 which suggests the feasibility of 
mAb150 binding to the folded protein (Figs.3H-iii, Fig.S5A). Similar 
mapping of full-length AnxA2 linear sequence did not qualify any po-
tential epitopes across all 5 platforms, except a minor core overlapping 
sequence between 145 and 170 aa position (Fig.S5B). These results 
demonstrated the presence of a dominant and most favored immuno-
genic AnxA2 epitope in proximity of its N-terminal. 
AnxA2 expression networks and protein interactions assign a context 
of involvement in active migratory modes but not in passive collective 
cell migration 
To identify the molecular interactors of Anxa2 which facilitate its 
functions in cancer cells, we immunoprecipitated AnxA2-bound proteins 
in A4 cell lysates with mAb150 and followed it up with MS/MS. This 
Fig. 1. Target identification, localization, and specificity of mAb150 in A4 cells. A-i. Immunoblotting of A4 whole cell lysates with mAb150; A-ii,A-iii. Cross- 
immunoprecipitation (IP) followed by probing of A4 lysate and Ax1 protein with mAb150 and commercial AnxA2 antibody and relevant controls; A-iv, A-v. 
Representative IB of mAb150 and commercial AnxA2 antibody with pure human recombinant Anxa2 protein and A4 lysates; A-vi, Avii. Localization of mAb150 
target across membrane (Mem), cytoplasm (Cyto) and nuclear (Nuc) subcellular fractions (CD24, B-actin and H3A are respective controls) in A4 cells; B-i, ii. Anxa2 
expression profiling through immunofluorescence staining and flow cytometry respectively; B-iii, B-iv. Cytotoxicity of mAb150 in A4 cells (MTT) and xenografts 
respectively; B-v. Significant reduction of AnxA2 expressing tumor cells following six doses of mAb150 treatment (18 mg/Kg) with 4 days of recovery between 
consecutive doses. For all experiments and wherever relevant, IgM isotype control (Sigma-Aldrich # M-5909) was used. *P<0.05; **P<0.01; ***P<0.001. 
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revealed α-enolase (ENO1), pre-mRNA splicing factor (SF2), Gelsolin 
(GSN) and histones H2A, H3, H4 as interacting partners of AnxA2 
(Fig. 4A; [12,25]). Assessment of genes co-expressed with AnxA2 in The 
Cancer Genome Atlas (TCGA Agilent platform; 598 tumor samples) 
ovarian cancer dataset identified 4 strong positively correlated genes 
(0.5>R2<− 0.5) viz. PLAU, PMP22, EMP1, and S100A10 which were 
validated in A4 cells (Figs.4B-C). Relaxing the threshold 
(0.35>R2<− 0.35) further identified 291 positively correlating genes 
including those associated with the extracellular matrix (ECM) and 
epithelial to mesenchymal transition (EMT) viz., COL11A1, COL6A2, 
COL6A3, COL5A1, COLA1A, FBN1, SPARC, FN1, COL5A2, VCAN, 
THBS2, ITGA11, MMP2, SNAI2, FAP (Fig.4D). Due to the association of 
these processes with cancer metastasis we explored the effects of 
mAb150 in possibly inhibiting metastasis. We observed that treatment 
with mAb150 severely diminished migratory and invasive properties of 
A4 cells as compared to untreated controls (Figs.S7A, S7B, S7C). To 
some extent, the reduced migratory capabilities may be also be attrib-
uted to the cytotoxic effects of mAb150 as is evident through membrane 
damage and nuclear fragmentation in A4 cells (Figs.S7D) and further 
substantiated as reduced cell viabilility during wound healing (S7E). 
We further investigated the differential association of AnxA2 corre-
lating genes in ovarian cell lines with a mesenchymal (A4, CP70) vs. 
epithelial (OVCAR3, OAW42) phenotype. ANXA2, EMP1, PMP22, 
S100A10, PLAU, SF2 and GSN transcripts were expressed at higher 
levels in mesenchymal cells affirming their functional correlation with 
EMT; consequently, lower expression of SNAI2, DCN, FAP, FN, FBN1, 
SPARC, LOXL2 and S100A10 was evident in cell lines with an epithelial 
morphology (Figs.S8A-B). This affirmed an association of AnxA2 with a 
mesenchymal phenotype (Fig.S8C). These observations were further 
supported with an evaluation of the three discrete modes of migration 
(EMT, aCCM – sheet/active collective cell migration and pCCM - passive 
collective cell migration) that we previously identified in a panel of 
ovarian cancer cell lines. The latter included epithelial (E-OVCAR3), 
intermediate epithelial (iE-CAOV3), epithelial-mesenchymal hybrid (E/ 
M-PEO14), intermediate mesenchymal (iM-A4) and mesenchymal (M- 
OVMZ60) phenotypes represented in the corresponding cell lines [10]. 
Interestingly, the cytotoxic activity of mAb150 displayed a gradient of 
decreasing efficacies from the mesenchymal to epithelial phenotypes; 
OVMZ6 (nIC50:18μg), A4 (nIC50:19.5μg), PEO14 (nIC50:25.6μg), 
CAOV3 (nIC50:29.0μg) to the lowest for OVCAR3 (nIC50:70μg). In live 
wound healing imaging assays, A4 cell migration was maximally 
restricted by mAb150 treatment, followed by CAOV3 and OVMZ6, while 
OVCAR3 cells were possibly refractory due to their inability to actively 
migrate into the open wound area (Fig.4E; Supplementary Videos 
S1-S4). The mean velocity of migration was significantly hampered after 
mAb150 treatment of PEO14, A4 and OVMZ6 cells (Fig.4F). Subsequent 
analysis of nearest neighbors and migration trajectories identified a shift 
towards the aCCM mode of migration in A4, OVMZ6 and PEO14 cells as 
previously reported ([10]; Figs.S9A, S9B). Cumulative evaluation of 
mAb150 efficacy on cell migration was obtained by superimposition all 
these parameters through Principal Component (PC) analysis using 
quantifiable metrics of cell displacement (Final Y), velocity and nearest 
neighbors which affirmed strong responsiveness of OVMZ6, A4 and 
PEO14 cells to mAb150 treatment (Fig.4G). Conclusively, this suggests a 
Fig. 2. Correlation of AnxA2 expression with mAb150 cytotoxicity and epigenetic potentiation. A. Normalized IC50 values (nIC50) of mAb150 in cell lines; B. 
Correlation between reduction in AnxA2 expression and xenograft regression following mAb150 treatment segregates two clusters, Group a: low AnxA2 expression- 
low efficacy, Group b: high AnxA2 expression-high efficacy; C, D. Epigenetic potentiation for mAb treatment in terms of enhanced AnxA2 expression after individual 
and combined treatment with epigenetic drugs 5-Aza-dC or HMTase inhibitor (5 mM and 7 mmol respectively) in A4 (C, D-i) and OVCAR3 (C, D-ii) cells; *P<0.05; 
**P<0.01; ***P<0.001. 
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functional involvement of AnxA2 in active cell migration (aCCM and 
EMT) since mAb150 treatment maximally affected cells which migrated 
through these modes. 
Determination of cellular targets of mAb150 in xenograft tumors 
indicates minimal regenerative potential following mAb150 treatment 
While xenograft regression indicated specific targeting of AnxA2 
expressing cells, it did not reveal the extent of regenerative potential of 
residual tumor cells which evade treatment. To address this issue, we 
applied a previously established 3-level flow cytometry-based approach 
that resolves and identifies enriched populations in xenograft tumors 
following mAb150 treatment ([12,17]; S.Data 4; Figs.5Ai-5Aii). Briefly -  
i Label-chase of vital lipophilic membrane dye, PKH67 in xenografts 
resolved the proliferative hierarchy (Fig. 5-Aiii-top panel). Quiescent 
CSCs associated with maximal regeneration resided in PKHhi, pro-
genitors in PKHlo and differentiated cells in PKHneg fractions. 
mAb150 treatment led to significant reduction of the PKHhi fraction 
in A4, OVCAR3, PC3, MCF7, ME180, U373, A549, A431 xenografts 
(Fig.5B-i).  
ii Propidium iodide (PI) - based DNA content analysis identifies host 
(mouse), euploid and aneuploid tumor cells in xenografts (Fig.5A-iii- 
middle panel). mAb150 treatment led to decreased host and euploid 
fractions in xenografts (Fig.5B-ii).  
iii Hoechst-Pyronin Y staining-based DNA-RNA content analysis along 
with PI staining resolves cell cycle phases (notably segregation of G0 
from G1) within ploidy-based fractions (Fig.5Aiii-bottom panel). 
Significant reduction of Euploid G0 concurrently with increased 
Euploid G1 cells was evident in mAb150 treated A4 xenografts, while 
in other xenografts both fractions were reduced (Fig.5B-iii). 
Sorting of the various A4 xenograft cell fractions was performed to 
evaluate residual regenerative potential following mAb150 treatment (3 
doses, 150 μg protein/site for 2 weeks followed by 1 week of recovery). 
Capabilities of regenerating suspended spheroids, adherent colonies, 
anchorage independent colonies in soft agar and migration to mediate 
wound healing were significantly reduced after mAb150 treatment 
especially in the PKHhi and PKHlo cells (Figs.5C-i-iv). Limiting dilution 
assays further indicated that following either a 3-dose (3D) or 6-dose 
therapeutic regimen of mAb150, residual tumor regenerative potential 
is maximal in the PKHhi euploid fractions that could be assigned a sig-
nificant tumor initiating frequency, while a much higher number of 
PKHlo euploid cells are required to regenerate tumors following treat-
ment, and PKHneg cells failed to generate any tumors (Figs.5D-i, D-ii). 
Further, mapping AnxA2 expression onto these fractions identified 
differential responses of AnxA2pos and AnxA2neg populations within A4 
xenografts (Fig. 6A-i). AnxA2pos regenerative hierarchy and aneuploidy 
cells were directly targeted by mAb150 (Fig.6A-ii), while an increased 
Fig. 3. Determination of mAb150 reactive epitope. A-i. Coomassie blue stained SDS-PAGE protein gel of recombinant protein lysates of Ax1, Ax2 and Ax3, A-ii. 
Immunoblotting of Ax1, Ax2 and Ax3 recombinant lysates probed with mAb150 and consequently with Anti-GST (A-iii); B-i. Immunoblotting of Ax4 and Ax5 re-
combinant lysates probed with mAb150 and consequently with Anti-GST (B-ii); C. Coomassie blue stained SDS-PAGE protein gel of recombinant protein lysates of 
Ax4, Ax5 and Ax6 (left panel) and immunoprecipitated with mAb150 (right panel), followed by immunoblotting with mAb150 (D-i) and Anti-Anxa2 (D-ii); E. 
Immunoblotting of recombinant protein lysates of Ax7 and Ax8 with mAb150 (E-i) and Anti-GST(E-ii); F. ELISA-based profiling of mAb150 reactivity with Ax4, Ax5, 
Ax7 and Ax8 fragments; G. ELISA-based profiling of reactivity with synthetic peptides Ap1-Ap12 of (G-i) mAb150, and (G-ii) commercial AnxA2 C-terminal antibody 
(sc-166,762); H-i. Mapping of mAb150 epitope on AnxA2 1–50 aa sequence by 5 different servers, indicating (H-ii) overlapping epitope region (annotated by 
different color lines) in proximity of the N-terminal region (a core overlapping epitope is highlighted by gray background, annotated as *), (H-iii). Molecular surface 
view model that indicates its location (marked in pink) on the AnxA2 protein (green). 
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G0 fraction in AnxA2neg cells suggested likelihood of progenitors 
entering quiescence (possibly tumor dormancy); drug refractory prolif-
erative cells were localized in the euploid fraction (Figs.6A-iii-iv). Re-
sidual regenerative potential was majorly seen in cells of the AnxA2neg 
fraction, with a few AnxA2pos cells (likely to be drug resistant) retained 
in vitro spheroid, adherant and soft agar colony formation capabilities 
(Figs.6B-i-ii). Such residual functionality was also observed in other 
tumor xenografts (Figs.6C-i-iii). Conclusively, resolution of intra-tumor 
cell heterogeneity and differential AnxA2 expression identified specific 
fractions that may either be sensitive, refractory, or resistant to mAb150 
treatment. 
We combined all three levels of resolution to compute an 18-cell 
population ‘tumor cytotype’ that strengthens drug evaluation vis-à-vis 
prediction of residual regenerative potential within tumors (Fig.S6A; 
[12,25]). mAb150 treatment perturbed the tumor cytotype by targeting 
all sub-populations of the PKHhi, PKHlo and host fractions. A striking 
observation was of possible re-entry into the cell cycle of the otherwise 
dormant G0-PKHhi cells (Fig.S6B-inset). A comparative pan-cancer 
analysis indicated similar patterns of responses in all xenografts, 
wherein targeting of PKHhi fraction was associated with emergence of 
cycling populations; surprisingly the PKHneg fraction was better targeted 
in OVCAR3, A431, PC3, A549, ME180 and U373 xenografts (Fig.S6C). 
Profiling of AnxA2 expression within this cytotype affirmed reduced 
frequency of all AnxA2pos fractions following treatment, accompanied 
by an increased cycling of residual AnxA2pos and AnxA2neg PKHhi pop-
ulations (Fig.S6D). Concurrently, in the AnxA2neg fraction, while PKHneg 
cells were reduced following treatment, PKHlo cells were increased 
following mAb150 treatment (Figs.S6E-i-ii). The common feature across 
all tumors following treatment with mAb150 was the emergence of 
cycling CSC populations. However, those in the AnxA2neg fraction are 
indicated to have lower regenerative potential (most progenitor 
sub-populations are arrested at G1-S) than in the AnxA2pos fraction. This 
profiling provided an additional dimension of differential cycling as an 
end-point measure of residual regenerative potential, besides affirming 
the target specificity of mAb150 across cancer types. 
Fig. 4. Identification of interacting partners and co-expression network towards functional evaluation of AnxA2. A. Representative mAb150 immunoprecipitated 
proteins stained with Coomassie Blue; B. Correlation plot for positive correlating genes with ANXA2 gene expression in HGSC-TCGA dataset; C. Validation of 
predicted and immunoprecipitated AnxA2 correlating proteins by immunoblotting; D. Plot indicating correlation between EMT signature AnxA2 hub genes; E. 
Representative migration capabilities estimated as percent in vitro open wound area for OVCAR3, CAOV3, PEO14, A4 and OVMZ6 cells following mAb150 exposure, 
serum starved (denoted by ss) cells used as control; F. Representative box plots of mean migratory velocity (pixels/hr) comparison between 1: Control (Serum 
starved) and 2: mAb150 treated cells; G. Principal component (PC) analysis of time-lapse imaging-based migration data of control and mAb150 treated cells, filled 
and empty shapes indicate control and mAb150 treated cells respectively. *P<0.05; **P<0.01; ***P<0.001. 
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mAb150 prolongs tumor ascites formation and survival in a PDX model of 
ovarian cancer 
Finally, we evaluated mAb150 efficacy in a Patient Derived Xeno-
graft (PDX) model established using ovarian ascites derived from a pa-
tient with recurrent high-grade serous ovarian adenocarcinoma {data 
unpublished}. High AnxA2 expression was noted in peritoneal tumor 
ascites cells and multilayer spheroids developed in this model (Figs. 
S10A-B). Development of tumor ascites was delayed on administering 6 
intraperitoneal doses of mAb150 to 35 days in this model from 21 days 
in vehicle treated control mice (Fig.S10C). Correspondingly, survival of 
mAb150 treated mice was extended from ~ 81 days (in vehicle treated 
controls) to 110 days (Fig.S10D). To further the effect of combination 
therapy, PDX mice were treated with 6 cycles of Paclitaxel (25 mg/Kg) 
monotherapy in combination with mAb150 (18 mg/Kg). This not only 
enhanced survival, but also the quality of life of mice since a reduced 
volume of peritoneal tumor ascites harbouring fewer number of tumor 
spheroids were observed under the treatment regime (Fig.S10E). This 
makes it pertinent to further evaluate other drug combinations with 
mAb150 towards improved treatment strategies and possibly achieve 
remission. 
Discussion 
Lack of target specificity and emerging resistance to chemotherapy 
has advocated for antibody-based therapeutic regimes in several ma-
lignancies, especially advanced-stage metastatic cancers. In the present 
study, we applied these principles to evaluate the efficacy of a mono-
clonal antibody developed in our lab. Identification of membrane bound 
AnxA2 as the target of mAb150 is suggestive of high antigenicity of the 
protein. The epitope recognized by mAb150 was localized to the AnxA2 
N-terminal region (residues 11–20), which is crucial for its membrane 
localization and protein-protein interactions [9,26]. Of the multiple 
post-translational modifications reported in this region tyrosine 23 
phosphorylation is known to promote EMT in pancreatic cancer 
[27–29]. A p11-dependent membrane translocation event is identified 
in this event, while phosphorylation is mediated via a feedback loop 
mechanism at the membrane [26–28]. AnxA2 usually functions with its 
partner S100A10 as a mono-/ hetero-tetramer [26]. The heterotetramer 
interacts with tissue plasminogen activator to facilitate conversion of 
Fig. 5. Evaluation of mAb150 efficacy in A4 xenograft cell sub-populations following treatment (3 doses, 18 mg/kg; 1-week recovery between and after doses). A-i, 
ii. Schematic and corresponding dot blots in flow cytometry data for resolution of cell fractions- Top panel: label-chase identifies Pkhhi (CSCs), PKHlo (progenitors and 
aneuploid cells), PKHneg (differentiated cells). Middle panel: PI based-DNA content resolves Host, Euploid and Aneuploid populations. Lower panel: Hoechst-Pyronin 
Y-PI based DNA-RNA quantification resolves 5 fractions viz. 1: Euploid G0, 2: Aneuploid G0, 3: Euploid G1, 4: Euploid S-G2/M and Aneuploid G1, 5: Aneuploid S −
G2/M populations, A-iii. Fold-reduction following mAb150 treatment of the cell populations described in 3A-i; B. Heatmap representations of consolidated fold- 
change in the frequency of individual fractions between 8 treated xenografts and appropriate controls across - i. PKH regenerative hierarchy-based, ii. Ploidy- 
based and, iii. Ploidy-Cell cycle phase-based fractions; C. Evaluation of residual regeneration in mAb150 treated A4 xenografts assayed for- i. spheroid forma-
tion, ii. adherent colony formation, iii. soft agar colony formation, iv. Wound healing assay; D. Limiting dilution assays (3D – 3 doses of mAb150, 6D – 6 doses of 
mAb150 as described in methods), i. Tumor regenerative potential 0f 5000, 10,000 and 20,000 residual cells of sorted fractions, ii. Tumor initiating frequencies of 
residual cells of sorted fractions. 1:PKHnegHost, 2:PKHnegEu, 3:PKHnegAneu, 4:PKHloEu, 5:PKHloAneu, 6:PKHhi. *P<0.05; **P<0.01; ***P<0.001. 
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plasminogen to plasmin that leads to fibrinolysis [27]. It also regulates 
membrane dynamics during endocytosis-exocytosis and membrane 
trafficking, besides participating in EMT [30]. Inhibition of these in-
teractions by synthetic peptides, immunotherapeutic agents, siRNA or 
aptamers abolish membrane localization and restrict cancer progression 
[30–35]. Elevated levels of AnxA2 in tumors correlate with drug resis-
tance and poor prognosis in multiple metastatic tumors including renal, 
pancreatic, liver, urothelial, and lung cancers [36–39] (https://www. 
proteinatlas.org/ENSG00000182718-ANXA2/pathology). As a secre-
tory protein, circulatory AnxA2 levels are reported to be elevated in 
metastatic hepatocellular and breast cancers [40]. 
The outcome of mAb150-mediated targeting of AnxA2 was similar to 
the earlier results obtained from multiple AnxA2-inhibitory approaches. 
The efficacy of mAb150 treatment across a panel of cancer cell lines and 
xenografts directly correlated with AnxA2 expression, which was re-
flected by lower IC50 values in AnxA2-high cells along with a high 
specificity in blocking its target. Given the fact that the mAb150-specific 
epitope lies within a functionally important region of the molecule, we 
anticipated and established that mAb150 treatment adversely affected 
the metastases-promoting functions of AnxA2. Analysis of AnxA2 
expression networks and interactors indeed identified multiple co- 
expression partners of key EMT genes/modulators that were further 
validated. Tumor cells expressing AnxA2 were targeted by mAb150, and 
the treatment led to delayed migration through the aCCM and EMT 
modes, besides invasion. This assigns a cell phenotype-based context to 
the efficacy of Anxa2 inhibition, which is a novel feature of the present 
study. We additionally report that epigenetic potentiation of AnXA2 by 
5-Aza-dC or HMATi in combination with mAb150 improved the efficacy 
of mAb150 and may deliver further prognostic benefits as is reported in 
immunotherapy [41,42]. Therapeutic relevance of mAb150 was finally 
affirmed through findings in PDX models in which formation of ascite-
s/intraperitoneal spheroids (marked by high AnxA2 levels) were 
significantly delayed along with extended survival in treated mice. 
Several preclinical cancer drug candidates often fall short of 
achieving therapeutic success and revoke remission. This is partly 
attributed to a lack of cytotoxicity end-point assays to identify drug- 
responsive cell fractions and map residual regenerative potential 
within treated tumors. Our earlier resolution of the heterogeneity of 
tumor cell populations and drug target expression determines respon-
siveness through multi-dimensional evaluation of a new drug candidate 
or combination, with due consideration of the drug refractory pop-
ulations within tumors [12]. On evaluating the efficacy of mAb150 on 
this platform, treatment was seen to significantly reduce the frequency 
of quiescent CSCs and progenitor subsets. This seemed to be a two- 
pronged attack, specific targeting due to high expression of AnxA2 in 
these cells that leads to reduced clonogenicity, along with re-entry of the 
quiescent populations into the cell cycle that make them more vulner-
able to drug targeting. AnxA2 is reported to be co-expressed with CSC 
markers including DCLK1, LGR5, and CD44 on circulating CSCs in 
clinical samples [43], suggesting AnxA2 expression in these populations 
made them vulnerable to mAb150 neutralizing activity. A similar 
mechanism was recently validated in prostate tumors where mAbs for 
angiogenin and plexin-B2 sensitized CSCs for chemotherapy by dimin-
ishing their stemness features [44]. Such sensitization could drive 
Fig. 6. Effect of mAb150 treatment on A4 xenografts vis-à-vis drug target (AnxA2) expression and altered fold-change in the respective, sorted tumor fractions 
following treatment. A-i. Schematic of AnxA2neg and AnxA2pos cell fractions in A4 xenografts; A-ii. Regenerative hierarchy, A-iii. Ploidy, A-iv. Cell cycle fractions; B. 
Comparison functional assays for capability to form spheroids (B-i) and soft agar colonies (B-ii) of the regenerative hierarchies in AnxA2neg and AnxA2pos cell 
fractions; C. Heatmap representation of C-i. Spheroid formation, C-ii. adherent colony formation and C-iii. soft agar colony formation capability of residual cells in 
each of the PKH regenerative hierarchy fractions across 8 tumor types (1:PKHneg; 2:PKHlo; 3:PKHhi). NS- Not Significant. 1: Euploid G0, 2: Aneuploid G0, 3: Euploid 
G1, 4: Euploid S + G2/M and Aneuploid G1, 5: Aneuploid S − G2/M. *P<0.05; **P<0.01; ***P<0.001. 
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exhaustion of the CSC-progenitor repertoire in xenografts, which reflects 
on the ability of mAb150 to perturb tumor heterogeneity by targeting 
regenerative sub-populations in tumors. Thereby, mAb150-driven 
AnxA2 neutralization could be an effective strategy for tumor regres-
sion and block disease relapse, especially in ovarian cancer. 
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